# Cardinal Health Moat

Status: published. Policy: company-analysis-1.

Cardinal Health demonstrates repeat customer demand, improving operating earnings and a profitable generics program, but the passages do not establish a durable relative cost advantage or material customer switching barriers. GMPD has weak pricing power: price increases and surcharges failed to recover all cost increases in fiscal 2024–2026, with competitive and contractual constraints explicitly disclosed. Subsequent profit growth shows operating resilience despite these constraints. The substantial OptumRx contract expiration demonstrates customer relationships are contestable, but does not establish a company-wide absence of moat.

## cost_advantage

The generics program, including joint sourcing, is a current contributor to profit improvement. A sourcing cost advantage is plausible but unproven because the disclosures do not isolate sourcing savings or compare costs with competitors.

Durability: Positive generics contributions were disclosed in fiscal 2024, 2025 and 2026. This establishes recurring contribution, not durable cost superiority.

Risks: Customer consolidation, manufacturer pricing changes and contract renewals can redistribute sourcing benefits. Customers can also develop internal supply management capabilities.

Invalidation: The potential cost-advantage thesis would be undermined by disclosed sourcing costs matching or exceeding alternatives, or repeated contract repricing that eliminates sourcing benefits despite stable volumes.

Competitors: Not established
## switching_costs

Existing-customer growth and acquired practice-support platforms suggest continuing customer relationships, but do not demonstrate material switching costs. This remains a potential mechanism rather than an established advantage.

Durability: Repeat demand is evidenced across periods; renewal economics, switching expenses and customer dependence are not established.

Risks: OptumRx contracts representing 17% of fiscal 2024 revenue expired, adversely affecting profit and cash flows. Practice-support acquisitions also face integration and provider-retention risks.

Invalidation: A switching-cost thesis would be undermined by repeated material customer departures, demonstrated easy substitution, or renewals requiring economically significant concessions. Documented implementation costs and sustained renewals on favorable terms would support it.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/721371/000072137126000038/cah-20260630.htm](https://www.sec.gov/Archives/edgar/data/721371/000072137126000038/cah-20260630.htm) · 2026-08-11
- [https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/cah-20251231.htm](https://www.sec.gov/Archives/edgar/data/721371/000072137126000006/cah-20251231.htm) · 2026-02-05
- [https://www.sec.gov/Archives/edgar/data/721371/000130817926000402/cah-20260921.htm](https://www.sec.gov/Archives/edgar/data/721371/000130817926000402/cah-20260921.htm) · 2026-09-21
- [https://www.sec.gov/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm](https://www.sec.gov/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm) · 2025-08-12
- [https://www.sec.gov/Archives/edgar/data/721371/000072137124000056/cah-20240630.htm](https://www.sec.gov/Archives/edgar/data/721371/000072137124000056/cah-20240630.htm) · 2024-08-14
- [https://www.sec.gov/Archives/edgar/data/721371/000072137125000130/cah-20250930.htm](https://www.sec.gov/Archives/edgar/data/721371/000072137125000130/cah-20250930.htm) · 2025-10-30

[JSON](https://beanvest.com/stock/cah/moat.json)